CONCORDBIO - Technical Analysis with Chart Patterns & Indicators
← Back to ListKey Parameters
⭐ Technical Rating: 2.8
Show all parameters (20 more)
🧾 Chart Verdict
Short-term entry zones could be established around 1,450 ₹ – 1,475 ₹, utilizing the support offered by the 50-DMA as a base. A stop-loss order should be placed just below this level, say at 1,410 ₹, to protect capital during a potential pullback. Exit price zones would target the next resistance levels around 1,550₹ - 1,600₹ if the upward momentum continues, but significant volume and sustained breaks above 1,704₹ would be necessary to confirm this move. Overall, the stock demonstrates moderate upside potential but requires cautious monitoring due to the high valuation and recent profit decline.
✅ Positive
The price action shows a recent bounce off the 50-DMA, suggesting potential support at this level. Volume is elevated compared to the weekly average, reinforcing the momentum of this move. The RSI is currently neutral, indicating that the short-term trend isn’t yet overbought or oversold.
⚠️ Limitation
Despite the recent bounce, the stock remains significantly overvalued relative to its industry peers based on the P/E ratio of 55 versus 34.8. This elevated valuation makes it vulnerable to a correction if market sentiment shifts. Furthermore, the sharp decline in last quarter’s profits warrants careful consideration.
📉 Company Negative News
MarketsMojo rated Concord Biotech ‘Hold,’ and the investment in Celliimmune is focused on long-term cancer research; this does not suggest immediate profitability. Scanx.trade reported that Concord Biotech is investing in Fermentation APIs, a segment with potentially lower margins than its existing business.
🏭 Industry
The pharmaceutical sector, particularly API manufacturing and biotech research, typically trades at higher P/E ratios due to growth potential and innovation. While the industry is generally robust, profitability remains key, which seems to be a current concern for Concord Biotech.